Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2023; 14(8):1272-1281. doi:10.7150/jca.79377 This issue Cite

Research Paper

The aMAP Score is an Independent Risk Factor for Intermediate-stage Hepatocellular Carcinoma: A Large Retrospective Cohort Study

Yaying Chen1*, Yanhong Shi1*, Linbin Lu1, Xuewen Wang1, Qin Lin2, Yihong Lin2, Ruiqi Wang3, Hongwu Zhu4, Peichan Zheng5,6, Xiong Chen1✉ on behalf of Fujian-biomarkers Study Group

1. Department of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China.
2. Department of Oncology, The 900th Hospital of the People's Liberation Army Joint Service Support Force, Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China.
3. Department of Gastroenterology, Xiamen Humanity Hospital, Xiamen, China.
4. Department of Gastroenterology, General Hospital of Southern Theater Command, People's Liberation Army of China, Guangzhou, Fujian, China.
5. Fujian Key Laboratory of Drug Target Discovery and Structural and Functional Research, Fuzhou, China.
6. Fujian Center for Safety Evaluation of New Drug, Fujian Medical University, Fuzhou, China.
* These authors contribute equally to the work.

✉ Corresponding author: Xiong Chen, MD, Department of Oncology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China. Tel: 86-0591-22859444; Fax: 86-0591-22859444; Email: cxiongzpcedu.cn

Citation:
Chen Y, Shi Y, Lu L, Wang X, Lin Q, Lin Y, Wang R, Zhu H, Zheng P, Chen X. The aMAP Score is an Independent Risk Factor for Intermediate-stage Hepatocellular Carcinoma: A Large Retrospective Cohort Study. J Cancer 2023; 14(8):1272-1281. doi:10.7150/jca.79377. https://www.jcancer.org/v14p1272.htm
Other styles

File import instruction

Abstract

Graphic abstract

Background: A less effective nomogram for patients with intermediate-stage hepatocellular carcinoma (HCC) to predict overall survival (OS) is available. This study aimed to investigate the role of age-male-albumin-bilirubin-platelet (aMAP) scores in the prognosis of patients with intermediate-stage HCC and develop an aMAP score-based nomogram to predict OS.

Methods: Data on newly diagnosed intermediate-stage patients with HCC at Sun Yat-sen University Cancer Center between January 2007 and May 2012 were retrospectively collected. Independent risk factors affecting prognosis were selected by multivariate analyses. The optimal cut-off value for the aMAP score was determined using X-tile. The survival prognostic models were presented by the nomogram.

Results: For the 875 patients with intermediate-stage HCC included, the median OS was 22.2 months (95% CI 19.6-25.1). Patients were classified into three groups by X-tile plots (aMAP score < 49.42; 49.42 ≤ aMAP score < 56; aMAP score ≥ 56). Alpha-fetoprotein, lactate dehydrogenase, aMAP score, diameter of main tumor, number of intrahepatic lesions, and treatment regimen were independent risk factors for prognosis. A predicted model was constructed with a C-index of 0.70 (95% CI: 0.68-0.72) in the training goup, and its 1-, 3-, and 5-year area under the receiver operating curve were: 0.75, 0.73, and 0.72. The validation group of the C-index is 0.82. Calibration graphs showed good consistency between the actual and predicted survival rates. The decision curve analysis suggested the clinical utility of the model, which may help clinicians guide clinical decision-making.

Conclusion: The aMAP score was an independent risk factor for intermediate-stage HCC. The aMAP score-based nomogram has good discrimination, calibration, and clinical utility.

Keywords: hepatocellular carcinoma, intermediate-stage HCC, BCLC stage B, overall survival, aMAP score, predicted model, nomogram, TACE

Citation styles

APA
Chen, Y., Shi, Y., Lu, L., Wang, X., Lin, Q., Lin, Y., Wang, R., Zhu, H., Zheng, P., Chen, X. (2023). The aMAP Score is an Independent Risk Factor for Intermediate-stage Hepatocellular Carcinoma: A Large Retrospective Cohort Study. Journal of Cancer, 14(8), 1272-1281. https://doi.org/10.7150/jca.79377.

ACS
Chen, Y.; Shi, Y.; Lu, L.; Wang, X.; Lin, Q.; Lin, Y.; Wang, R.; Zhu, H.; Zheng, P.; Chen, X. The aMAP Score is an Independent Risk Factor for Intermediate-stage Hepatocellular Carcinoma: A Large Retrospective Cohort Study. J. Cancer 2023, 14 (8), 1272-1281. DOI: 10.7150/jca.79377.

NLM
Chen Y, Shi Y, Lu L, Wang X, Lin Q, Lin Y, Wang R, Zhu H, Zheng P, Chen X. The aMAP Score is an Independent Risk Factor for Intermediate-stage Hepatocellular Carcinoma: A Large Retrospective Cohort Study. J Cancer 2023; 14(8):1272-1281. doi:10.7150/jca.79377. https://www.jcancer.org/v14p1272.htm

CSE
Chen Y, Shi Y, Lu L, Wang X, Lin Q, Lin Y, Wang R, Zhu H, Zheng P, Chen X. 2023. The aMAP Score is an Independent Risk Factor for Intermediate-stage Hepatocellular Carcinoma: A Large Retrospective Cohort Study. J Cancer. 14(8):1272-1281.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use